MedPath

To compare the efficacy of escitalopram versus escitalopram and melatonin combination therapy in treating major depressive disorder.

Phase 4
Conditions
Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified
Registration Number
CTRI/2024/07/070641
Lead Sponsor
Indira Gandhi Medical College Shimla
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients diagnosed with MDD but without history of insomnia according to DSM V criteria.

2.Patients of either sexes above 18 years of age.

Exclusion Criteria

1.Patients with organic cause of depression such as stroke, Alzheimer’s, Parkinsons, intracranial tumors, epilepsy etc.

2.Patients with severe depressive episodes with psychotic symptoms.

3.Pregnant and lactating females.

4.Patients in which these medications are contraindicated

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.To compare the efficacy of combination therapy of escitalopram and melatonin versus escitalopram alone in the treatment of MDD using Hamilton Depression Rating Scale (HDRS). <br/ ><br>2.To compare the safety of the combination therapy of escitalopram and melatonin versus escitalopram monotherapy using AE (Adverse Event) and ADR (Adverse Drug Reaction) in adult patients of MDD. <br/ ><br>Timepoint: 3 months and 6 months <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
To assess the quality of life of patients of MDD taking escitalopram versus escitalopram and melatonin combination therapy using WHO BREF questionnaire.Timepoint: 3 months and 6 months
© Copyright 2025. All Rights Reserved by MedPath